FDA Wants More Data Before Approving Clinical Cell Culture Ltd.'s ReCell

January 16, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Tissue engineering specialist Clinical Cell Culture's (ASX:CCE, C3) share price took a blow today, in the wake of a request by the US Food and Drug Administration (FDA) for more performance data before it can approve C3's ReCell for sale in the US.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Australia

Food and Drug Administration (FDA)